Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Sept. 22 — Purdue Pharma LP and AnaBios Corp. Sept. 22 said they intend to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel drug compounds for the treatment of chronic pain.
The joint research and development effort would leverage Purdue Pharma’s intellectual property and lead compounds, combined with AnaBios’ Phase-X technology, the companies said.
The Phase-X technology enables the discovery of novel drugs directly in human tissues, bypassing animal experimentation, the companies said. AnaBios generates highly valuable and predictive human data that ensure the selection of the most effective and safest drugs before investing in expensive and time consuming clinical trials, they said.
“The prospect of combining AnaBios’ unique platform and Purdue Pharma’s top quality chemistry exemplifies the powerful nexus of technology-based discovery and industry collaboration,” Mark Timney, president and chief executive officer of Purdue Pharma, said. “This creative partnership fits in well with our strategic plan to continue development of our existing therapeutic programs and ultimately bring value to patients suffering from pain and to healthcare providers.”
Purdue Pharma is based in Stamford, Conn. and AnaBios is based in San Diego.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)